Nordea Investment Management AB Buys 14,262 Shares of Boston Scientific Corporation $BSX

Nordea Investment Management AB raised its stake in Boston Scientific Corporation (NYSE:BSX) by 11.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 143,313 shares of the medical equipment provider’s stock after buying an additional 14,262 shares during the period. Nordea Investment Management AB’s holdings in Boston Scientific were worth $13,984,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Steph & Co. bought a new position in Boston Scientific during the 3rd quarter worth approximately $25,000. Financial Consulate Inc. bought a new stake in shares of Boston Scientific in the 3rd quarter valued at $25,000. FWL Investment Management LLC acquired a new stake in Boston Scientific in the second quarter worth $26,000. Sound Income Strategies LLC raised its holdings in shares of Boston Scientific by 90.9% during the second quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock valued at $27,000 after purchasing an additional 120 shares during the period. Finally, Kilter Group LLC bought a new position in shares of Boston Scientific during the 2nd quarter worth about $30,000. 89.07% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on BSX. Royal Bank Of Canada lifted their price objective on shares of Boston Scientific from $125.00 to $130.00 and gave the company an “outperform” rating in a report on Wednesday, December 17th. BTIG Research reiterated a “buy” rating and issued a $132.00 target price on shares of Boston Scientific in a research note on Friday, November 21st. Canaccord Genuity Group dropped their price target on shares of Boston Scientific from $132.00 to $131.00 and set a “buy” rating on the stock in a research report on Wednesday, December 17th. Truist Financial dropped their target price on shares of Boston Scientific from $130.00 to $120.00 and set a “buy” rating on the stock in a research report on Thursday, December 18th. Finally, Robert W. Baird raised their target price on Boston Scientific from $123.00 to $128.00 and gave the company an “outperform” rating in a research report on Wednesday, October 1st. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, Boston Scientific presently has an average rating of “Buy” and an average target price of $125.21.

Boston Scientific Price Performance

Shares of NYSE:BSX opened at $90.00 on Friday. The company has a 50 day moving average of $97.14 and a 200 day moving average of $100.46. The stock has a market cap of $133.41 billion, a P/E ratio of 48.13, a P/E/G ratio of 1.66 and a beta of 0.67. The company has a current ratio of 1.51, a quick ratio of 0.96 and a debt-to-equity ratio of 0.47. Boston Scientific Corporation has a 12 month low of $85.98 and a 12 month high of $109.50.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, October 22nd. The medical equipment provider reported $0.75 EPS for the quarter, topping the consensus estimate of $0.71 by $0.04. Boston Scientific had a return on equity of 19.46% and a net margin of 14.43%.The company had revenue of $5.07 billion during the quarter, compared to analyst estimates of $4.97 billion. During the same quarter in the previous year, the firm earned $0.63 earnings per share. Boston Scientific’s revenue was up 20.3% on a year-over-year basis. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. As a group, sell-side analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Insider Activity

In other Boston Scientific news, Director Ellen M. Zane sold 12,891 shares of the stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $98.28, for a total value of $1,266,927.48. Following the completion of the sale, the director owned 24,134 shares in the company, valued at approximately $2,371,889.52. This trade represents a 34.82% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Arthur C. Butcher sold 17,313 shares of the business’s stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the transaction, the executive vice president owned 23,600 shares in the company, valued at $2,396,580. This represents a 42.32% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 93,095 shares of company stock valued at $9,305,450. Insiders own 0.50% of the company’s stock.

Key Headlines Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Strategic rationale — the acquisition gives BSX immediate scale in mechanical thrombectomy and neurovascular devices, expanding its cardiovascular portfolio and entry into fast‑growing vascular segments, which could drive medium‑term revenue and market-share gains. Boston Scientific announces agreement to acquire Penumbra, Inc.
• Neutral Sentiment: Complementary M&A and product wins — recent smaller deals (Valencia Technologies) and regulatory wins (Farapoint PFA catheter, CE mark for coils) continue to diversify growth engines but are incremental compared with the Penumbra transaction. Boston Scientific to buy incontinence device maker Valencia
• Neutral Sentiment: Analyst views supportive — some analysts reiterated buy ratings and highlighted long‑term upside from the company’s EP and electro‑physiology franchise, partially offsetting integration concerns. Farapoint PFA Approval Strengthens EP Ecosystem and Supports Buy Rating
• Negative Sentiment: Market reaction and financing concerns — investors sold BSX as the deal is large (~$14.5B enterprise value), raising near‑term concerns about dilution, integration costs and leverage; Penumbra shares rose sharply while BSX declined on the news. Boston Scientific to acquire Penumbra in $14.5B deal
• Negative Sentiment: Bearish options flow — unusually large put buying (≈35,600 puts, ~161% above typical daily volume) signals elevated short‑term investor hedging or bearish speculation, adding downward pressure.
• Negative Sentiment: Regulatory / litigation flags for target — shareholder‑investigation notices related to Penumbra were circulated, which could add legal/transaction risk or distract management during integration. BRODSKY & SMITH SHAREHOLDER UPDATE

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.